Novotech Earns Great Place to Work® Certification in the United States
19.9.2024 17:56:00 CEST | Business Wire | Press release
Novotech, a global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been certified as a Great Place to Work® in the United States. This award reflects Novotech’s commitment to fostering a flexible, inclusive, and innovative work environment where employees feel supported and empowered to contribute to the future of medical research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919886365/en/
Novotech is a Great Place to Work Certified in the USA (Graphic: Business Wire)
The certification is based on direct feedback from employees and highlights the supportive and collaborative culture Novotech has built in its U.S. offices. It underscores the company’s dedication to ensuring that its team members thrive, both professionally and personally.
What makes Novotech a Great Place to Work?
- A welcoming and inclusive work culture where diversity is celebrated.
- Opportunities for career growth, development, and learning.
- A strong emphasis on flexibility and work-life balance.
- A solutions-focused approached to teamwork to ensure high quality outcomes for our clients.
- Recognition and appreciation of individual and team contributions to the company’s success.
"Our employees are the heart of Novotech, and their satisfaction is our top priority," said Angela Edwardson, Chief People Officer of Novotech. "This certification is a testament to the environment we’ve worked hard to create, one where innovation thrives, and our people feel valued and supported."
The certification, while focusing on Novotech’s U.S. operations, mirrors the company’s global commitment to creating a positive workplace culture across all its locations. Novotech is now planning to expand this certification process to additional regions, reinforcing its dedication to making Novotech a great workplace for all employees worldwide.
"We’re grateful to our U.S. team for their participation in this certification process, and to all Novotech employees for their hard work and dedication," continued Edwardson. "We look forward to celebrating many more achievements together as we continue to grow and innovate globally."
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-sized pharma companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Global Biotech CRO Company of the Year Award 2024, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award 2023.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240919886365/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Responding to Customer Demand, Starlink High-Speed Connectivity Now Available as an Aftermarket Option on the Cessna Citation Ascend; 560XL Series Achieves EASA Certification21.4.2026 14:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced at AERO Friedrichshafen the availability of Starlink highspeed connectivity as an aftermarket upgrade for the Cessna Citation Ascend, the newest aircraft in the bestselling Cessna Citation 560XL series, following the Federal Aviation Administration’s issuance of AeroMech’s Supplemental Type Certificate (STC). In addition, the Cessna Citation 560 XL fleet — including the XLS Gen 2, XLS+, XLS and Excel — has received European Union Aviation Safety Agency (EASA) certification for Starlink installation at Textron Aviation’s European service centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420017406/en/ Responding to customer demand, Starlink high-speed connectivity now available as an Aftermarket option on the Cessna Citation Ascend; 560XL series achieves EASA certification AeroMech’s STC utilizes Starlink’s high-speed internet technology connec
Moody’s Advances Decision-Grade Credit Intelligence Across Enterprise AI Workflows, Powered by Microsoft 365 Copilot21.4.2026 14:00:00 CEST | Press release
Moody’s decision-grade intelligence now available directly in the AI-powered tools where market participants work Moody’s Corporation (NYSE: MCO) today announced the next phase of its strategic partnership with Microsoft, integrating Moody’s decision-grade intelligence directly into Microsoft AI solutions. The milestone expands the collaboration from co-innovation to scaled, workflow-embedded distribution of Moody’s decision-grade intelligence across the enterprise environments where its customers work every day. “For over 115 years, Moody’s has served as the intelligence layer that financial professionals turn to when making consequential decisions,” said Rob Fauber, President and Chief Executive Officer of Moody’s. “By embedding that intelligence directly into Microsoft’s AI solutions at enterprise scale, we’re making decision-grade analysis available not just to specialists, but to every person across an organization who needs it.” The integrations operate across two channels. Using
Redslim expands its global footprint into Latin America21.4.2026 14:00:00 CEST | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Latin America (LATAM) region, marking the next step in its growth strategy to support multinational brands and retailers across every major market. Following its recent expansion into APAC, this move reinforces Redslim’s momentum in building a truly global presence, reflecting growing demands from international clients for a trusted partner delivering reliable and AI-ready data and insights at scale. The expansion includes the appointment of Alejandro Merlo as Regional Director and Javier Gonzalez as Regional Manager for the region. Latin America represents a strong growth opportunity for global consumer brands, but also one of the most complex data environments. Rapid digital adoption and shifting consumer behaviours are driving demand for reliable market intelligence, while fragmented retailer structures and country-specific data landscapes make consis
Adtran’s SDG router portfolio receives FCC conditional approval, supporting ongoing broadband expansion21.4.2026 14:00:00 CEST | Press release
News summary: FCC approval exempts Adtran’s SDG router portfolio from Covered List restrictions through October 1, 2027 Decision enables uninterrupted shipments, authorizations and deployments across current and next-generation SDG platforms Regulatory clarity supports long-term SDG investment and rollout planning Adtran today announced that its service delivery gateway (SDG) carrier-grade router portfolio has received conditional approval from the FCC’s Public Safety and Homeland Security Bureau, formally exempting the platforms from FCC Covered List restrictions through October 1, 2027. The decision places Adtran among the first router manufacturers to achieve this designation under the FCC’s national security review process. By ensuring continued access to Adtran’s SDG technology, the approval enables service providers to maintain deployment momentum, reduce operational risk and invest confidently in the long-term expansion of broadband networks while navigating evolving regulatory
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs21.4.2026 14:00:00 CEST | Press release
Partnership enables timely access to botensilimab plus balstilimab through France’s government-reimbursed Autorisation d’Accès Compassionnel (AAC) pathway and paid named-patient programs (NPP) in select countries Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial supply company, today announced the exclusive appointment of BAP Pharma as Agenus’ global partner for botensilimab (BOT) plus balstilimab (BAL) authorized global access programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421146539/en/ The partnership supports compliant, patient-focused access to BOT+BAL through authorized pathways where permitted by local regulations. Effective immediately, BAP Pharma will serve as Agenus’ exclusive partner for the coordination of BOT+BAL global access program operations, including program requests, case coordination, distribution logistics, and re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom